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Are Expired Drugs Dangerous?
A recent drug information question we received was: “Are expired drugs dangerous?” The short answer is that
not all expired drugs are dangerous. Some drugs that degrade easily (e.g. sublingual nitroglycerin, insulin, liquid antibiotics) would be dangerous if expired because of loss of potency and subsequent loss of therapeutic
benefit. Others that decompose into a different chemical compound (e.g. aspirin degrades to salicylic acid)
could be dangerous. To understand the issue more closely, there are 2 questions to consider:
(1) Who sets the expiration dates for prescription drugs in their original packaging?
Expiration dates are set by the manufacturer of a prescription drug and not by the healthcare authorities. The
company may choose time period that is determined based on the results of "in-house" testing. Some people,
however, feel that the time period chosen by the company is done in an effort to facilitate product sales. Most
pharmaceutical manufacturers choose two to three years after the date of manufacture as the expiration date.
The expiration date assigned to a medication by the manufacturer is not the date after which it has "gone bad."
It is the date after which the manufacturer cannot guarantee that the product meets standards for stability
(maintaining identity, strength, quality, purity). Usually, all products should maintain at least 90% potency till
the shelf life mentioned on them.
(2) Who sets the expiration dates for prescription drugs that are transferred from original packaging
into a prescription container?
In 1985, the United States Pharmacopoeia (USP) began recommending that pharmacists set expiration dates at
no more than one year if they are dispensing drugs in a container other than the original one. In 1997, it became a USP requirement that, unless otherwise specified in compendium standards, the expiration date on a
dispensed medication should be no later than the expiration date on the manufacturer’s container or one year
from the dispensing date, whichever is earlier. How a medication is stored affects its long-term stability.
Exposure to light, air, humidity, and temperature extremes can affect the degradation rate of a drug. The expiration date assigned by the manufacturer or dispensing pharmacist assumes that the medication will be stored
properly, with in the closed container it was actually dispensed in and stored at the appropriate temperature. In
reality, many patients store medications in less than ideal environments: warm, humid areas (bathroom cabinet), window sills (lighted areas), various locations in the interior of automobiles (hot) etc.
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These storage conditions lend credence to pharmaceutical manufacturers’ insistence that "conservative"
expiration dating is warranted.
Therefore the main idea is that not to take risk in using expired medications unless confirmed by healthcare
authorities and manufacturer about the extension of shelf life beyond expiration date only under special circumstances like shortage of drugs or anticipation of large inventory losses as a result of expiry.
Syed Shamim Raza (Senior Pharmacist II)

Why Report Adverse Drug Reactions?
•
•
•
•

Because the data about Asians is very limited as compared to Caucasians
Many ADRs are preventable
It helps in restricting use of unsafe drugs
It helps Pharmacy & Therapeutic Committee to make and implement protocols for safe use of medicines

Report ADRs, “Patient’s Safety” should be our first priority!

ADR Reportage—Year wise Presentation
Year
# of ADRs

2000

2001

2002

2003

2004

43

87

55

40

78

Specialty of person reporting
Pharmacist

17

09

38

27

49

Physician

24

78

11

08

29

Nurses

02

-

06

05

-

Age of the patients distributed in each year
Max. age

72 years

83 years

80 years

73 years

84 years

Min. age

11 months

2 years

1 year

1 year

8 months

Sex of the patient
Males #

23

50

26

29

31

Females #

20

37

29

11

47

Severity (outcome) of ADRS (%)
Recovered
Fatal

100

98

100

97

96

-

2

-

3

4

Compiled by: Drug & Poison Information Centre, Department of Pharmacy Services—AKUH
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Categories of ADRs reported Trough Year 2000-2004
Analgesics 4%
GI Drugs 7%

Antibiotics
Chemotherapeutic Agents
Hematological Agents

CNS drugs 10%

Cardiovascular Drugs
CNS drugs
Cardiovascular Drugs
10%

GI Drugs
Analgesics
Antibiotics 48%

Hematological Agents
10%
Chemotherapeutic
Agents 11%

Compiled by: Drug & Poison Information Centre, Department of Pharmacy Services—AKUH

NEWS ALERT! Use of Promethazine (Phenargan) in Children
Dear Health Care Professional:
Based on a review of adverse events for Phenergan in pediatric patients, the Food and Drug Administration has
requested that the following changes, be made to the product prescribing information effective from 31st
January 2005.
CONTRAINDICATIONS :
Phenergan Tablets, injections and syrup are contraindicated for use in pediatric patients less than two years of
age.
WARNINGS
Phenergan should not be used in pediatric patients less than 2 years of age because of the potential for fatal
respiratory depression. Postmarketing cases of respiratory depression, including fatalities have been reported
with its use in children < 2 years old. A wide range of weight-based doses of Phenergan have resulted in respiratory depression in these patients. Caution should be exercised when administering Phenergan to the pediatric
patients < 2 years old and older. It is recommended that the lowest effective dose of Phenergan be used and
concomitant administration of other drugs with respiratory depressant effects be avoided.
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Important Drug Warning - Herceptin (Trastuzumab)
Caution for Oncologists and Cardiologists
This is updated cardiotoxicity information related to the use of HERCEPTIN® (trastuzumab),
obtained from the National Surgical Adjuvant Breast and Bowel Project (NSABP) study (B-31), a randomized,
Phase III trial that was conducted in 2043 women with operable, HER2 over expressing breast cancer (IHC 3+
or FISH+). This study demonstrated a significant increase in cardiotoxicity in patients who were randomized
to the HERCEPTIN-containing arm as compared to patients who received chemotherapy alone.
A preliminary analysis of the safety data from Study NSABP B-31 was presented at the annual meeting of the
American Society of Clinical Oncology (ASCO) in May 2005, during the presentation of a joint analysis of
Study NSABP B-31 and the North Central Cancer Treatment Group (NCCTG) study (N9831). Study NSABP
B-31 was intended, in part, to characterize cardiotoxicity associated with HERCEPTIN use and to assess the
value of serial cardiac monitoring during HERCEPTIN therapy as a predictor of cardiotoxicity and as an aid to
early identification of cardiac toxicity.
Based on preliminary data and analyses through April 2005, 6.8% of patients were unable to initiate
HERCEPTlN per the protocol because of decreased LVEF or symptoms of cardiac toxicity experienced during
the AC portion of therapy. Among the evaluable patients who had adequate cardiac function and initiated
HERCEPTIN, 30.5% required at least one dose delay because of asymptomatic decrease in LVEF or cardiac
symptoms. In 18.6% of patients, HERCEPTIN was discontinued prior to the completion of 1 year of therapy
because of asymptomatic decrease in LVEF (14.3%) and symptomatic cardiac dysfunction/other cardiac toxicity (4.3%). In addition, a statistically significant increase in the 3-year cumulative incidence of New York
Heart Association Class III and IV congestive heart failure and cardiac death was observed in patients who
received the HERCEPTIN-containing regimen (4.1%) compared with control (0.8%). There were no cardiac
deaths observed in patients who received the HERCEPTIN-containing regimen and 1 cardiac death was
observed in the control arm. Final analysis of the cardiac safety data collected in Studies NSABP B-31 and
NCCTG N9831 is ongoing.
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